HOOK (HOOKIPA Pharma) LT-Debt-to-Total-Asset: 0.01 (As of Jun. 2025)

What is HOOKIPA Pharma LT-Debt-to-Total-Asset?

HOOKIPA Pharma HOOK 50 LT-Debt-to-Total-Asset is 0.01 as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 50/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. HOOKIPA Pharma's long-term debt to total assests ratio for the quarter that ended in Jun. 2025 was 0.01.

HOOKIPA Pharma's long-term debt to total assets ratio declined from Jun. 2024 (0.03) to Jun. 2025 (0.01). It may suggest that HOOKIPA Pharma is progressively becoming less dependent on debt to grow their business.

HOOKIPA Pharma (OTCPK:HOOK) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

HOOKIPA Pharma LT-Debt-to-Total-Asset Related Terms

HOOKIPA Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for HOOKIPA Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma LT-Debt-to-Total-Asset Chart

HOOKIPA Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.05

0.02

0.00

HOOKIPA Pharma Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.02	0.00	0.01	0.01

50GF Score

HOOKIPA Pharma Inc HOOK

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

HOOKIPA Pharma LT-Debt-to-Total-Asset Calculation

HOOKIPA Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.323	/	82.545
	=	0.00

HOOKIPA Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (Q: Jun. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2025 )	/	Total Assets (Q: Jun. 2025 )
	=	0.298	/	52.706
	=	0.01

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.01 mean?

HOOKIPA Pharma (HOOK) has a LT-Debt-to-Total-Asset of 0.01 as of Jun. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on HOOKIPA Pharma and its competitors.

Is HOOKIPA Pharma's LT-Debt-to-Total-Asset too high?

HOOKIPA Pharma's current LT-Debt-to-Total-Asset is 0.01. Overall, HOOKIPA Pharma has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does HOOKIPA Pharma's LT-Debt-to-Total-Asset compare to COCP and LNAI?

HOOKIPA Pharma's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is HOOKIPA Pharma stock overvalued right now?

Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. HOOKIPA Pharma's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current LT-Debt-to-Total-Asset is 0.01 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HOOKIPA Pharma (HOOK) Overvalued in 2026?

Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued. The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78. GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.

Key valuation signals for HOOK:

LT-Debt-to-Total-Asset: 0.01
GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
GF Score™: 50/100 with 7 warning signs

No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HOOKIPA Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies COCP LNAI CYCN BIVI ZEOX CTXR JUNS PASG LEXX GDTC VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118

Website https://www.hookipapharma.com

HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).

50GF Score

Get the complete analysis for HOOK

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15

Price

$2.78

GF Value

View HOOK Analysis

See LT-Debt-to-Total-Asset data for all stocks →